Because of the reported potential worsening of OSA after GH therapy [20, 21], consensus guidelines recommend a screening PSG before initiation and within 3–6 months after the start of GH therapy in all children with PWS [22]. The gene discussed is GH1; the disease is obstructive sleep apnea syndrome.